Peptide Monograph

GHRP-6

Growth Hormone Releasing Peptide-6

At a Glance

Mechanism of Action

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as a potent growth hormone secretagogue by binding to the growth hormone secretagogue receptor type 1a (GHS-R1a), also known as the ghrelin receptor. It was among the first synthetic GH-releasing peptides developed, with its discovery by Bowers and colleagues in the 1980s preceding the identification of ghrelin as the endogenous ligand for GHS-R1a.[1]

Upon binding GHS-R1a on anterior pituitary somatotroph cells, GHRP-6 activates the phospholipase C/inositol trisphosphate (PLC/IP3) pathway, leading to increased intracellular calcium and subsequent release of stored growth hormone. This mechanism is distinct from and complementary to the growth hormone-releasing hormone (GHRH) pathway, which operates primarily through cAMP. When GHRP-6 is administered concurrently with a GHRH analog, the resulting GH release is synergistic rather than merely additive.[2]

As a ghrelin mimetic, GHRP-6 also activates GHS-R1a in the hypothalamus and gastrointestinal tract, triggering a significant increase in appetite and hunger. This orexigenic effect is a hallmark of GHRP-6 and is more pronounced than with more selective GH secretagogues such as ipamorelin. GHRP-6 also stimulates the release of cortisol and prolactin, reflecting its relatively low selectivity among the GHRP family. These off-target hormonal effects distinguish GHRP-6 from newer, more selective compounds.[3]

GHRP-6 is considered a first-generation growth hormone secretagogue. Its role has been largely superseded in research by more selective compounds such as GHRP-2 (greater GH potency with reduced cortisol/prolactin effects) and ipamorelin (highly selective GH release without hunger, cortisol, or prolactin elevation). However, GHRP-6 retains value as a pharmacological tool for studying GHS-R1a signaling and as a diagnostic agent for GH deficiency assessment.[4]

Evidence Summary

GH Release Characterization

Bowers et al. demonstrated that GHRP-6 produces robust, dose-dependent GH release in humans when administered intravenously or subcutaneously. In healthy volunteers, a single IV bolus of 1 mcg/kg produces a significant GH peak within 15–30 minutes, with GH levels returning to baseline within 2–3 hours. The GH response to GHRP-6 is amplified when co-administered with GHRH, producing a synergistic release that is several-fold greater than either compound alone.[1][2]

Dose-Response and Hormonal Profile

Arvat et al. systematically characterized the dose-response relationship of GHRP-6 in healthy subjects and patients with GH deficiency. At doses of 1–2 mcg/kg IV, GHRP-6 reliably stimulates GH release while also producing measurable increases in cortisol, prolactin, and ACTH. These hormonal side effects are dose-dependent and distinguish GHRP-6 from more selective GH secretagogues.[3]

Diagnostic Use

GHRP-6 has been used as a provocative test for GH deficiency in clinical research settings. Its reliability in stimulating GH release makes it a useful diagnostic tool, though it has not been standardized or widely adopted for clinical GH deficiency testing in most countries. The GHRP-6 + GHRH combined test has been proposed as a more reliable alternative to insulin tolerance testing for GH deficiency diagnosis.[4][5]

Primary Uses (in Research)

Based on the available literature, GHRP-6 has been investigated for the following applications:

• GH deficiency diagnosis — As a provocative agent in GH stimulation testing, alone or in combination with GHRH. Reliable GH release makes it useful for differentiating GH-deficient from GH-sufficient individuals.[4]
• GH axis research — Pharmacological tool for studying the GHS-R1a signaling pathway, pituitary somatotroph function, and the interaction between GHRP and GHRH pathways.[1]
• Body composition studies — Investigation of chronic GH secretagogue administration on lean body mass, fat mass, and metabolic parameters in research settings.[2]
• Appetite and ghrelin pathway research — Used as a tool to study orexigenic signaling through the ghrelin receptor and its downstream effects on food intake and energy balance.[3]

Contraindications

Standard Protocols

Timing is considered important in research protocols: GHRP-6 is typically administered on an empty stomach (fasting for at least 30 minutes before and after) to maximize GH pulse amplitude, as food intake — particularly fats and carbohydrates — can blunt the GH response. Common administration times are upon waking, pre-workout, and before bed.[2]

Common Stacks & Synergies

In the peptide research community, GHRP-6 is frequently combined with other compounds. The following stacks are commonly discussed but have no published human clinical evidence supporting their combined therapeutic use:

• GHRP-6 + GHRH analog (CJC-1295 or Mod GRF 1-29) — The most widely used combination. GHRP-6 (acting via GHS-R1a/PLC) and GHRH analogs (acting via GHRH-R/cAMP) produce synergistic GH release that exceeds either compound alone by several-fold. This synergy is well-documented in published research.[2]
• GHRP-6 + Ipamorelin — Some protocols combine first-generation (GHRP-6) and third-generation (ipamorelin) GH secretagogues, though the rationale is unclear since both target GHS-R1a. Ipamorelin is generally preferred as a standalone due to its cleaner side effect profile.
• GHRP-6 + MK-677 (Ibutamoren) — MK-677 is an oral, non-peptide GHS-R1a agonist. Combining it with GHRP-6 is generally discouraged due to overlapping mechanisms and potential for excessive GHS-R1a stimulation.

Preparation & Administration

GHRP-6 is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 5 mg or 10 mg of peptide. It must be reconstituted with bacteriostatic water (BAC water) before injection.

Reconstitution

For a standard 5 mg vial reconstituted with 2.5 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 200 mcg. For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

Subcutaneous injections should be administered using a 29–31 gauge insulin syringe. Common injection sites include the abdominal subcutaneous tissue (periumbilical area), avoiding the immediate area around the navel. Rotate injection sites to avoid lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Side Effects & Adverse Events

Commonly reported side effects:

• Intense hunger: The most prominent and distinguishing side effect. GHRP-6's ghrelin-mimetic activity produces a marked increase in appetite within 20 minutes of administration. This effect is more pronounced than with any other GHRP.[3]
• Water retention: Mild to moderate fluid retention, often manifesting as puffy appearance or increased body weight.
• Cortisol elevation: Measurable increases in serum cortisol following administration. Chronic elevation may contribute to insulin resistance and other hypercortisolism-related effects.
• Prolactin elevation: Dose-dependent increase in prolactin levels, potentially leading to gynecomastia or lactation with chronic use at high doses.[3]
• Numbness and tingling: Transient paresthesias in hands and feet, likely related to acute GH release.
• Joint pain: Arthralgia associated with GH-mediated fluid retention in joints.
• Injection site reactions: Redness, swelling, or mild pain at the injection site.
• Dizziness and lightheadedness: Reported occasionally, particularly with the first dose.

Drug Interactions

No formal drug interaction studies have been conducted with GHRP-6 in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Insulin and oral hypoglycemics — GH elevates blood glucose via insulin resistance. Diabetic patients using insulin or sulfonylureas may require dose adjustments. Monitor blood glucose closely.
• Corticosteroids — GHRP-6 itself elevates cortisol. Concurrent exogenous corticosteroid use may amplify hypercortisolism-related adverse effects.
• Somatostatin analogs (octreotide, lanreotide) — Somatostatin suppresses GH release and will antagonize the effects of GHRP-6. Concurrent use is counterproductive.
• Dopamine agonists (cabergoline, bromocriptine) — These agents suppress prolactin. They may be used to manage GHRP-6-induced prolactin elevation, but no formal interaction data exists.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Always use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use.

Legal & Regulatory Status

• FDA (United States) — Not approved for any therapeutic indication. Not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption."
• WADA (World Anti-Doping Agency) — Prohibited at all times under class S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Athletes subject to anti-doping testing should not use GHRP-6.
• European Union — Not approved as a medicinal product. Regulatory status varies by member state. Generally available as a research chemical.
• Australia (TGA) — Not approved. Classified as a Schedule 4 prescription-only substance under the Poisons Standard.

Open Questions

Significant gaps remain in the GHRP-6 evidence base. Key unresolved questions include:

• Therapeutic obsolescence — Whether GHRP-6 has any remaining clinical utility given the development of more selective GH secretagogues (ipamorelin, GHRP-2) with fewer off-target effects.
• Long-term safety of chronic GHS-R1a agonism — The consequences of prolonged ghrelin receptor activation on appetite regulation, metabolic health, and cancer risk are not known.
• Optimal combination protocols — While GHRP-6 + GHRH synergy is well-documented, the optimal dosing ratios and timing for maximizing GH pulsatility while minimizing cortisol/prolactin effects have not been systematically determined in humans.
• Diagnostic standardization — Whether the GHRP-6 (or GHRP-6 + GHRH) stimulation test should be standardized as a clinical GH deficiency diagnostic remains debated among endocrinologists.

Bibliography

1. Bowers CY, Momany FA, Reynolds GA, Hong A. "On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone." Endocrinology. 1984;114(5):1537-1545. doi:10.1210/endo-114-5-1537. PMID:6425169.
2. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. "Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone." J Clin Endocrinol Metab. 1990;70(4):975-982. doi:10.1210/jcem-70-4-975. PMID:2108187.
3. Arvat E, Di Vito L, Broglio F, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E. "Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans." J Endocrinol Invest. 2000;23(8):493-495. doi:10.1007/BF03343763. PMID:11021763.
4. Ghigo E, Arvat E, Muccioli G, Camanni F. "Growth hormone-releasing peptides." Eur J Endocrinol. 1997;136(5):445-460. doi:10.1530/eje.0.1360445. PMID:9186261.
5. Camanni F, Ghigo E, Arvat E. "Growth hormone-releasing peptides and their analogs." Front Neuroendocrinol. 1998;19(1):47-72. doi:10.1006/frne.1997.0158. PMID:9465289.